Content about Fera Pharmaceuticals

June 17, 2013
Perrigo to acquire Fera's ophthalmic portfolio for up to $129 million

Perrigo Co. will pay up to $129 million to buy Fera Pharmaceuticals' portfolio of ophthalmic products, Perrigo said.

ALLEGAN, Mich. — Perrigo Co. will pay up to $129 million to buy Fera Pharmaceuticals' portfolio of ophthalmic products, Perrigo said Monday.

Perrigo said the acquisition from Locust Valley, N.Y.-based Fera included an upfront payment of $93 million and milestone payments of about $36 million. The products include generic ophthalmic sterile ointments and solutions and generated sales of more than $30 million in 2012.

September 16, 2011
Kevin Wingerter joins Fera

Fera Pharmaceuticals has appointed a new director of national accounts.

NEW YORK — Fera Pharmaceuticals has appointed a new director of national accounts.

The drug maker said that Kevin Wingerter, who most recently served as senior buyer of pharmaceutical merchandising at Walmart, has joined the company. Wingerter brings more than 20 years of experience in procurement of both branded and generic pharmaceuticals, Fera said.

June 27, 2011
Garamycin ophthalmic solution enters market

Fera Pharmaceuticals has launched an ocular bacterial infections treatment.

NEW YORK — Fera Pharmaceuticals has launched an ocular bacterial infections treatment.

The company announced the launch of Garamycin (gentamicin sulfate) ophthalmic solution USP, designed to treat such infections as conjunctivitis, keratitis and blepharitis.

Last year, Fera broadened its Garamycin product offerings with the launch of preservative-free Garamycin ophthalmic ointment.

February 3, 2011
Puralube re-enters market

Fera Pharmaceuticals on Wednesday announced the reintroduction of the nonprescription dry-eye remedy Puralube ophthalmic ointment due to demand for the product.

NEW YORK — Fera Pharmaceuticals on Wednesday announced the reintroduction of the nonprescription dry-eye remedy Puralube ophthalmic ointment due to demand for the product.

“Puralube is a product that fits perfectly with our eye care portfolio,” stated Frank DellaFera, president of Fera. “We are so pleased to make Puralube available again, giving patients, pharmacists and physicians a cost-effective and reliable treatment option for dry-eye symptoms.”

December 7, 2010
Reporters Notebook, Chain Pharmacy 12/13/10

Supplier News — Fera Pharmaceuticals has recently launched two new topical ointments. The New York-based company has developed Ilotycin (erythromycin) and Garamycin (gentamicin) ophthalmic ointments, both for the treatment of bacterial infections of the eye. “Our goal is simple: to keep more quality healthcare choices alive for the people who need them,” company co-founder Frank DellaFera said.





October 17, 2010
Fera launches Garamycin

Fera Pharmaceuticals has launched a preservative-free ointment for treating bacterial infections of the eye, the...

NEW YORK Fera Pharmaceuticals has launched a preservative-free ointment for treating bacterial infections of the eye, the company said Monday.

 

Fera said the launch of Garamycin (gentamicin sulfate) was to meet an unmet need for a preservative-free version of the drug. The Food and Drug Administration had received reports of allergic reactions in infants who had received formulations of the drug with preservatives.

 

 

July 20, 2010
Fera acquires rights to investigational otomycosis treatment

Fera Pharmaceuticals has acquired rights to an investigational drug for treating a rare fungal ear...

July 5, 2010
Fera launches Neptazane

Fera Pharmaceuticals has launched an oral preventive treatment for glaucoma, Fera said Friday....

January 25, 2010
Fera launches erythromycin ophthalmic ointment

Fera Pharmaceuticals has launched a treatment for bacterial infections of the eye, the generic drug...

January 14, 2010
Fera launches eye infection treatment

An ointment for treating eye infections has become available, the drug’s manufacturer announced Friday....